ERBB2 and breast carcinoma: Only 5 of 28 HER2+ patients were diagnosed with HER2 positive breast carcinoma after October 2005, when anti-HER2 adjuvant therapy became a standard treatment for patients with HER2+ breast carcinoma in our institution.